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hospital. All prospective implants between June 23, 2006 and March 31, 2014 were included.
There were 11 132 implants during this period. Of these, 432 were excluded from the analysis because of missing information about the duration of HF symptoms. Baseline characteristics (epidemiological, laboratory, echocardiographic, and hemodynamic) were obtained for all patients. Patients were classified according to the duration of HF symptoms before implantation of MCS as AHF, sub-AHF, or Cr-HF if symptoms were present <1 month, 1 to 12 months, or >12 months, respectively.
The implantation strategy was categorized as bridge to transplant if patients were listed at the time of MCS; bridge to candidacy if patients were considered possible candidates for heart transplant but were not listed at the time of implantation; destination therapy if patients were not transplant candidates; and bridge to recovery if the implanting center determined that there was a likelihood for explantation of the device.
Statistical Analysis
The statistical significance of differences between categorical variables was evaluated using the χ2 test or Fisher exact test, and the difference between continuous variables was evaluated using 1-way ANOVA. The difference in survival between groups was analyzed using Kaplan-Meier plots, and survival curves were compared using the log-rank test with censoring for transplantation or device explant because of recovery. Competing outcome methodology was used to estimate the time-related probability of patient outcomes. 7 The effect of HF acuity on survival was determined using multiphase parametric hazard modeling. This multivariable hazard modeling methodology has been described previously in detail. 8 Both unadjusted and adjusted models were used to compare the mortality risk among the HF duration groups using the Cr-HF patients as the reference group. The adjusted model included preimplant risk factors identified in a prior report: age, body mass index, mechanical ventilator support, INTERMACS profile at the time of implantation, diabetes mellitus, dialysis at the time of implant, creatinine level, right heart dysfunction, right atrial pressure, bilirubin, ascites, history of prior cardiac surgery, concomitant surgeries at the time of MCS, and destination therapy as implant strategy and need for right ventricular assist device support at the time of left ventricular assist device (LVAD) implant. 9 Adverse events were calculated as rate per month and stratified in early or late events if they occurred before or after 3 months from implantation, respectively. Adverse events were compared among groups using the likelihood ratio test for comparing linearized rates. Statistical significance was considered when P<0.05.
Results
Of the 10 733 patients studied, 723 had AHF, 1077 had sub-AHF, and 8930 had Cr-HF. Baseline characteristics are presented in Table 1 . AHF and sub-AHF patients were significantly younger than Cr-HF patients. The frequency of female patients receiving MCS decreased as duration of HF increased, and the percentage of blacks receiving MCS was lowest in the AHF group. Patients with Cr-HF had a higher frequency of peripheral vascular disease and previous cardiac surgery than patients with AHF and sub-AHF. Left ventricular size measured by echocardiography was progressively dilated with increasing duration of HF. The severity of illness was highest in the AHF group, with 60% of patients in critical cardiogenic shock (INTERMACS profile 1) at the time of implantation. The frequency of extracorporeal membrance oxygenator support, intra-aortic balloon pump support, and mechanical ventilation was highest in the AHF group. The indication for device implantation was predominantly bridge to candidacy in the patients with AHF, whereas the patients with Cr-HF received MCS predominantly as destination therapy. The frequency of biventricular support was highest in the AHF group.
The unadjusted estimated survival at 1, 2, and 4 years for the 3 groups were as follows-AHF: 79%, 72%, and 58%; sub-AHF: 81%, 71%, and 51%; Cr-HF: 78%, 66%, and 45%, respectively (P=0.0065; Figure 1 ). The differences in survival at 4 years post implantation was more evident when only patients who survived >3 months post implantation were evaluated (conditional survival): 67%, 55%, and 48% (P<0.0001) for the AHF, sub-AHF, and Cr-HF groups, respectively ( Figure 2 ). Survival for those patients receiving continuous flow LVAD alone, continuous flow LVAD with temporary or permanent pulsatile, or continuous flow right ventricular assist device or total artificial heart (patients receiving durable pulsatile LVAD were excluded) was 63%, 54%, and 45% at 4 years for the AHF, sub-AHF, and Cr-HF groups, respectively (P<0.0001). When survival was compared among groups according to INERMACS profile, patients with INTERMACS profile 1, 2, and 3 had better survival in the AHF group when compared with the Cr-HF group (P<0.05).
Competing outcomes were different according to duration of HF symptoms. The proportion of patients who received heart transplantation in the AHF group was 29.1% at 1 year and 40% at 2 years post implantation, whereas in the Cr-HF group, these proportions were 22.6% and 34%, respectively (P=0.05). Explantation of device for recovery occurred more frequently in the AHF group with a proportion of 4.7% at 12 months post implantation with significantly lower rates for the sub-AHF and Cr-HF groups (P<0.05).
We identified an acute (early post implantation) and a constant (late post implantation) risk of death in patients who received MCS. Unadjusted multivariable analysis showed no significant effect of duration of HF on the hazard rates of death among groups both in the early and late phase post implantation. After adjusting for established risk factors of mortality after MCS, the adjusted multivariable model showed that duration of HF had no effect in the early period post implantation but significantly influenced the outcome in the late period post implantation with AHF patients having a survival advantage when compared with Cr-HF patients ( Table 2) .
The most frequent causes of death in the AHF, sub-AHF, and Cr-HF groups were similar (P=0.6). Cardiovascular: 21.1%, 23.7%, and 22.9%; neurological: 22.3%, 22.2%, and 18.5%; and multiorgan failure: 12.6%, 11.6%, and 15.1%, respectively.
Adverse events post MCS implantation differed according to duration of HF. Patients with AHF had an increased frequency of bleeding, infection, neurological dysfunction, respiratory failure, and renal dysfunction when compared with patients with sub-AHF and Cr-HF in the first 3 months post implantation. In the late phase, patients with AHF and sub-AHF had lower rates of bleeding, infection, and respiratory failure than patients with Cr-HF (Table 3 ).
Discussion
The most salient finding of this article is related to the improved survival in AHF patients who received MCS when compared with those with Cr-HF, in spite of higher level of disease severity and increased use of biventricular support. AST, ALT, and bilirubin data are shown as: median (interquartile range; n). AHF indicates acute heart failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BiVAD, biventricular assist device; BMI, body mass index; Cr-HF, chronic HF; ECMO, extracorporeal membrane oxygenator; IABP, intra-aortic balloon pump; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; ns, non significant; and TAH, total artificial heart. September 2015
Cr-HF is characterized by hemodynamic and neurohormonal changes that affect all organ systems. Chronic hypoperfusion and elevated filling pressures are associated with increased levels of catecholamines, angiotensin II, and aldosterone and increased inflammation. End-organ function is compromised and eventually leads to cardiorenal syndrome, hepatic dysfunction, malnutrition, cardiac cachexia, muscle wasting, and frailty, all of which have been associated with poor outcomes after MCS. [10] [11] [12] [13] [14] In the myocardium, chronically impaired hemodynamics and altered neurohormones lead to increased apoptosis and impaired regenerative mechanisms producing remodeling of the cardiac chambers with progressive dilation of the left ventricle. In the present report, 83% of patients who received durable MCS had >1 year of symptoms of HF. These patients were exposed to the deleterious effects and derangements produced by HF as evidenced by the severe dilatation of the left ventricle by echocardiography.
However, acute HF consists of a varied set of clinical syndromes characterized by a sudden decrease in cardiac function and end-organ hypoperfusion. Fifteen percent to 20% of all patients hospitalized because of HF do not have a prior history of cardiomyopathy likely representing new onset or AHF. Of patients presenting with new-onset HF associated with severely depressed left ventricular function, the mortality at 6, 12, and 18 months is 2.3%, 4.5%, and 6.8%, respectively. 15 Approximately 2% to 5% of patients admitted because of AHF present with hypotension and <1% present with cardiogenic shock. 16 The most serious presentation of AHF is severe refractory cardiogenic shock, which has a mortality of 50% to 80%. Patients who present with refractory cardiogenic shock or are stabilized with inotropic support may be in need of durable MCS. 17 Approximately 7% of patients in our cohort presented with AHF and cardiogenic shock that required the immediate implantation of MCS. Another group of patients (≈10%) had symptoms between 1 month and 1 year before implantation of MCS and had characteristics that fell between the extremes of AHF and Cr-HF.
Patients with AHF were ill at the time of implantation of MCS with 60% in INTERMACS profile 1. There was a higher frequency of extracorporeal membrane oxygenator support, IABP implantation, and mechanical ventilation. However, these patients were younger and had a lower frequency of peripheral vascular disease and prior cardiac surgeries, indicating that despite being severely and acutely ill, the burden of chronic diseases was lower in this group of patients. In addition, patients with AHF had the highest rate of right HF requiring right-sided MCS. It would be expected that the outcomes of patients with AHF would be worse than patients with Cr-HF given their higher clinical acuity and need for biventricular assist device support. However, we found that patients with AHF had the best estimated survival at 4 years post implantation.
Evaluation of the survival curves reveals that there are 2 distinct phases of mortality risk after implantation of MCS: an early phase characterized by an acute attrition in survival, followed by later phase of constant risk with more gradual decrease of survival after MCS. Kirklin et al 9 reported that factors, such as age, sex, body mass index, INTERMACS profile, previous stroke, and evidence of right heart dysfunction, were associated with an increased hazard ratio in the early phase, whereas factors, such as renal dysfunction and concomitant cardiac surgery, were associated with worse mortality in the late phase. Perusal of the estimated survival curves shows that patients with AHF appeared to have a slightly worse survival early on after implantation of MCS. However, this initial disadvantage was reversed in the chronic phase. One likely explanation for these differences may be that patients with AHF were more severely acutely ill at the time of implantation, and as a result their perioperatory mortality was higher than patients with Cr-HF. Once patients survived the early phase, their outcome would depend on intrinsic patient characteristics rather than on the severity of the disease. We performed a multivariable analysis adjusting for the above risk factors for early-and late-phase mortality. Shorter duration of HF was significantly associated with lower mortality in the late hazard phase. Thus, duration of HF appears as an important predictor of outcome after MCS. There may be other unmeasured factors that could drive this survival advantage in the AHF groups, such as frailty. These results are in concordance with our prior publication on the outcome of patients with peripartum cardiomyopathy who received MCS. In that population, patients with AHF were severely ill but had a comparable survival with other VAD patients in spite of the severity of their disease at the time of implantation. 18 The importance of clinical presentation of HF has been previously reported. Patients with recent-onset cardiomyopathy had generally favorable outcomes in the Intervention in Myocarditis and Acute Cardiomyopathy (IMAC)-2 study, with 88% transplant-free survival at 4 years. 19 A retrospective analysis of the Heartmate II bridge to transplant and destination therapy trials showed that patients with a shorter duration (<12 months) of HF had a higher probability of ventricular recovery. 20 Verbrugge et al 6 showed that the freedom of mortality or HF readmission was higher in patients with short duration of HF symptoms before the insertion of biventricular pacemaker, and this benefit was independent of left ventricular remodeling. In addition, McCarthy et al 21 described the outcome of patients with myocarditis according to the clinical presentation. Patients with fulminant myocarditis, who were severely ill and presented in cardiogenic shock, had better long term outcomes than patients with non-fulminant myocarditis who had a less severe presentation.
We performed additional analysis to evaluate the effect of chronicity of HF on the outcome if we eliminate the effect of the early hazard phase. When patients who survived more than 3 months were evaluated, their survival curves clearly separated according to duration of HF symptoms, and AHF patients had better outcomes than those with sub-AHF and Cr-HF respectively. INTERMACS profile 1 represents patients in acute cardiogenic shock and has been shown to predict worse survival after MCS. 22 As a result, the number of implants of MCS in patients with INTERMACS profile 1 has decreased in the last several years. 23 We evaluated the outcomes in patients with INTERMACS level 1, 2, and 3 and stratified them according to duration of HF. Patients with AHF had a better prognosis than patients with Cr-HF in each of these 3 levels of disease severity at the time of implantation. Thus, based on the information presented in this article, it may be inferred that patients with AHF may benefit from MCS implantation even if they are at INTERMACS profile 1 and should not be excluded from consideration based on severity of illness alone.
There were ethnic and sex disparities between AHF and Cr-HF patients who received MCS. The frequency of women receiving MCS with AHF was higher than those with Cr-HF. Whether this finding is related to differences in clinical presentation of HF in female patients or selection bias is unclear. Heidecker et al 24 described sex differences in myocardial gene expression of patients who presented with new-onset HF, which may account for the observed differences in the proportion of women presenting with AHF requiring MCS. It is not clear if the lower proportion of black patients receiving MCS in the AHF group represents a disparity in access to medical care or if there is a difference related to clinical presentation or progression of HF in this population.
Implantation strategy also differed among studied groups. Patients with AHF had the lowest frequency of bridge to transplant implants. This is likely because of severity of disease. Patients may not have been stable enough to be considered for heart transplantation, or healthcare teams did not know the patient long enough to evaluate psychosocial characteristics before transplant listing. Conversely, patients with AHF had the highest bridge to candidacy implantation, indicating that the physicians felt there was a reasonable chance that these patients may become transplant candidates. Transplantation rates after MCS were also different according to HF duration. Patients with AHF had the highest proportion of transplantation at 1 and 4 years in spite of having the lowest proportion of patients implanted as bridge to transplant. It has been previously described that there is a high frequency of myocardial recovery in patients with short duration of HF symptoms before MCS. 25 Our findings confirm that the highest rate of device explant occurs in AHF patients (~5%).
Limitations
Stratification by duration of HF symptoms used in this article was based on the data collected by INTERMACS and did not follow strict predetermined clinical criteria. Categorization of duration of HF was based on the local investigator's judgment.
In clinical practice, it may be difficult to determine the chronicity of HF, and it is possible that those patients classified as AHF could either represent true new-onset HF or Cr-HF not previously recognized that presented with an acute decompensation. Despite the limitations of definition, we feel our patients did stratify appropriately for the most part based on the fact that there was progressive cardiac dilatation by echocardiography in each successive group. Finally, this is a retrospective study based on a registry with the inherent limitations associated with registry analyses in general, including selection bias, our study cohort may represent a subgroup of the population (particularly in the AHF group). Patients with end-stage HF and cardiogenic shock, who had an unfavorable profile, would not have received an LVAD and thus would not be included in INTERMACS registry.
There were 432 (4%) patients who were excluded from the analysis because of an unknown duration of HF. These patients had some different clinical characteristics compared with the patients included in the study. On average, the excluded patients were slightly older, more likely to have a race of other/unknown, more likely to be INTERMACS patient profile level 1, and more likely to be bridge to candidacy. Although these differences were statistically significant, their impact on our conclusion should be minimal given the small proportion of excluded patients.
Conclusions
In summary, duration of HF symptoms is an important factor affecting survival in patients who receive MCS. Patients with AHF who received MCS have an overall better survival and higher frequency of transplantation and myocardial recovery, despite being sicker at the time of implantation. This has important implications on candidate selection. Although the trend over time has been to avoid durable MCS in patients with INTERMACS profile 1 presentations, our study suggests that duration of HF should be taken into account at the time of MCS evaluation. There may be a role for durable MCS in patients with short duration HF, even when they present with cardiogenic shock and critical illness. This requires further prospective study.
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